BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Takeda Pharmaceuticals' Alogliptin Wins FDA Approval


2/8/2013 11:00:30 AM

Los Angeles, CA (PRWEB) February 07, 2013 -- The U.S. Food and Drug Administration has just announced its approval for Nesina (alogliptin), a drug intended to manage blood sugar in people with type 2 diabetes. Nesina is manufactured by Takeda Pharmaceuticals, the same company behind Actos, another diabetes drug.

Bloomberg points out that Nesina may serve as a replacement to Actos, which has been the subject of increasing controversy since the FDA warned of possible health risks back in June of 2011. According to the FDA, the “use of the diabetes medication Actos (pioglitazone) for more than one year may be associated with an increased risk of bladder cancer.”

While Actos has been linked to certain health problems, the FDA is optimistic about Nesina. According to the FDA announcement, Nesina was shown to be safe and effective in 14 clinical trials, which were conducted with approximately 8,500 type 2 diabetes patients.

Personal injury lawyer Jeff Nadrich, of Nadrich & Cohen LLP, has been investigating and researching the effects of Actos for years, and just this week, Nadrich released a statement on his blog regarding the future of Nesina and diabetes patients.

According to Nadrich, “Clearly we need an effective drug to manage [type 2 diabetes], but time will only tell if Nesina proves to be a positive alternative to Actos. While the new drug has fared very positively in its initial clinical trials, we have seen time and time again that the real side effects often don’t present themselves until the drug is introduced into the general population.”

About Nadrich & Cohen: Jeffrey Nadrich is a personal injury attorney with Nadrich & Cohen, a California based law firm with offices in 18 locations across California. The firm has offices in Arcadia, Bakersfield, Fresno, Irvine, Long Beach, Modesto, Oakland, Oxnard, Palm Springs, Redding, Riverside, Sacramento, San Bernardino, San Diego, San Francisco, San Jose, Santa Rosa, and Tracy. Nadrich & Cohen handles all types of wrongful death and serious injury accident cases, including auto, truck, bus, motorcycle, and bicycle accidents, pedestrian collisions, boating accidents, dog bites, defective product cases and nursing home abuse. Victims are encouraged to call 1-800-718-4658 for a free consultation with a Nadrich & Cohen attorney.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES